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SISTEM RENIN ANGIOTENSIN DAN SISTEM SARAF SIMPATETIK DALAM 
PERKEMBANGAN TEKANAN BERLEBIHAN HIPERTROFI KARDIAK DAN 
PERANAN ADRENOSEPTOR SUBJENIS α1 DALAM HIPERTROFI 
VENTRIKEL KIRI 
 
 
ABSTRAK 
 
 
Hipertrofi ventrikel kiri (LVH) telah dikenal pasti sebagai faktor penyebab tunggal bagi 
penyakit arteri koronari, kematian mengejut, lumpuh dan kegagalan jantung. Kadar 
pertambahan penyakit hipertrofi ventrikel kiri bergabungan dengan hipertensi secara 
puratanya adalah sebanyak 40%. Oleh itu, pencegahan atau kemerosotan bagi LVH 
menjadi sasaran rawatan sama ada secara farmakologi, mekanikal, pembedahan atau 
manipulasi genetik. Tesis ini membincangkan tentang perkembangan LVH yang 
mengarah kepada kegagalan jantung dengan penekanan terhadap penglibatan sistem 
saraf simpatetik (SNS) dan sistem renin angiotensin (RAS). Faktor-faktor yang 
menyebabkan LVH yang boleh membawa kepada kegagalan jantung termasuklah 
lebihan mekanikal, pertambahan tekanan oksidatif, pertambahan penghasilan spesis 
oksigen yang reaktif (ROS), perubahan neurohormonal dan kecacatan aktiviti nitrogen 
oksida synthase (NOS). Perubahan neurohormonal yang berlaku semasa  
pengubahsuaian kardiak adalah disebabkan oleh rangsangan adrenergik α dan β, 
angiotensin, endotelin, dan faktor nekrosis tumor α. Peningkatan tahap angiotensinogen, 
ACE, ANGII dan mRNA reseptor ANGI yang telah ditunjukkan, mencadangkan aktiviti 
RAS yang berlebihan di dalam model kajan LVH. Selain daripada itu, penyekatan 
aktiviti RAS telah memberi faedah ke atas pertunjukan kardiak malah ke atas kadar 
penyakit dan kematian. Noradrenalin adalah faktor pertumbuhan yang sangat penting 
untuk kardiomiosit dan ia telah dicadangkan mengandungi kesan langsung ke atas 
 xxi
kardiomiosit tanpa mempengaruhi kesan selepas pengepaman darah masuk ke jantung 
(afterload). Dengan latar belakang ini, kajian ini telah diaturkan untuk menjelaskan 
sumbangan SNS dan RAS di peringkat vascular periferi dan saluran darah berintangan 
ginjal. Kajian ini telah dibahagikan kepada 3 bahagian dengan objektif penyelidikan 
yang berbeza dalam mencapai tujuan yang satu. Eksperimen vasopressor telah 
dijalankan untuk mengenali peranan adrenoseptor α dan reseptor AT1 serta 
mengenalpasti interaksi antara RAS dan SNS dalam vaskulatur periferi. Untuk 
mengetahui perkembangan LVH pada sela masa tertentu, beberapa eksperimen telah 
dijalankan dan adrenoseptor intrarenal dan AT1 telah dikaji melalui eksperimen yang 
telah dirancang secara spesifik untuk menyelidik reseptor α1 dan subjenisnya dalam 
vaskulatur ginjal dan buah pinggang. Dalam vaskulatur periferi, reseptor AT1 dan 
adrenoseptor α1  telah terlihat mengandungi mekanisma tindak balas yang kompleks di 
mana secara keseluruhannya RAS bertindak balas positif terhadap SNS dengan 
beberapa pengecualian. Selepas stenosis aorta, fungsi ventrikel kiri telah dimodulasi 
oleh SNS dan RAS. Fasa pertama terdiri daripada disfungsi sistolik dan kemudian 
diikuti oleh disfungsi diastolik. Peranan SNS telah dipertingkatkan dalam 
pengubahsuaian fungsi jantung semasa LVH dan antagonism SNS telah mengarah 
kepada fungsi ventrikel kiri yang lebih baik. Pada peringkat saluran darah berintangan 
ginjal, pelbagai perubahan subjenis α1 adrenoseptor telah dilihat yang mana telah 
menjana tindak balas yang kompleks terhadap reseptor AT1 di dalam ginjal. Peranan 
adrenoseptor subjenis α1D seolah-olah telah mendapat kepentingan asas dengan sedikit 
perubahan dalam peranan adrenoseptor α1A dan α1D.             
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RENIN ANGIOTENSIN SYSTEM & SYMPATHETIC NERVOUS SYSTEM IN 
THE PROGRESSION OF PRESSURE OVERLOAD CARDIAC 
HYPERTROPHY AND THE ROLE OF α1 ADRENOCEPTOR SUBTYPES IN 
THE CONTROL OF RENAL HAEMODYNAMICS IN LEFT VENTRICULAR 
HYPERTROPHY 
 
 
ABSTRACT 
 
 
Left ventricular hypertrophy (LVH) has been identified as an independent risk factor in 
coronary artery disease, sudden death, stroke and heart failure. The prevalence of LVH 
in patients with essential hypertension has been found to be 40% on average. Therefore, 
prevention and/or regression of LVH is a major therapeutic goal whether achieved by 
pharmacologic, mechanical, surgical or genetic means. This thesis discusses the 
progression of LVH that leads to heart failure with an emphasis on the involvement of 
sympathetic nervous (SNS) and the renin angiotensin systems (RAS) The pathogenesis 
of LVH leading to a failing heart might include mechanical overload, increased 
oxidative stress, increased production of reactive oxygen species (ROS), neurohormonal 
changes and impaired nitric oxide synthase activity. The neurohormonal changes that 
occur during this cardiac remodeling are caused by α and β adrenergic stimulation, 
angiotensin, endothelin and tumor necrosis factor α. Increased levels of 
angiotensinogen, ACE, ANGII and ANGI receptor mRNA have been shown which 
suggests an overactive RAS in experimental models of LVH. Moreover, inhibition of 
RAS has been shown to be of benefit for cardiac performance as well as morbidity and 
mortality. Noradrenaline is a potent growth factor for cardiomyocytes and it has been 
postulated to have a direct effect on cardiomyocytes without affecting afterload. With 
this background, this study sets out to elucidate the contribution of SNS and RAS at 
 xxiii
peripheral vasculature and renal resistance vessel level. The complete study was divided 
into three parts with different experiments aimed to achieve individual objectives. The 
vasopressor experiments were carried out to identify the role of α adrenoceptors and 
AT1 receptors and identify the interaction of RAS and SNS in the peripheral 
vasculature. To study the progression of LVH over a period of time some experiments 
were done. Thirdly, intra renal adrenoceptors and AT1 were studied in an experiment 
which was designed specifically to study the role of α1 adrenoceptors and their subtypes 
in the renal vasculature and kidney. It was found that in peripheral vasculature AT1 
receptors and α1 adrenoceptors have a complex feedback mechanism whereby in 
general RAS had a positive feedback on the SNS with a few exceptions. After aortic 
stenosis the left ventricular function is greatly modulated by both SNS and RAS. The 
initial phase constitutes of systolic dysfunction which is followed by diastolic 
dysfunction in later stage. The role of SNS is greatly enhanced in the modulation of 
cardiac function during LVH and antagonism of SNS leads to improved left ventricular 
function. At the renal resistance vessels, a multiple subtype shift of α1 adrenoceptor 
subtypes was observed which generated a complex feedback on the renal AT1 receptors. 
The role of α1D adrenoceptor subtype seemed to have gained functional importance in 
LVH with a minimal altered role of α1A and α1B adrenoceptors. 
 xxiv
CHAPTER 1 
 
INTRODUCTION 
 
 Heart failure is one of the leading causes of cardiovascular morbidity and 
mortality in the modern age. About 60-70% of the patients presented with congestive 
heart failure (CHF) have left ventricular systolic dysfunction. Rest of the patients who 
preserve left ventricular ejection fraction (LVEF) exhibit left ventricular diastolic 
dysfunction (Vasan et al., 1995).  
  
Heart failure can be defined as a clinical syndrome caused by an abnormality of 
the heart and recognized characteristic patterns of haemodynamic, renal, neural and 
hormonal responses accompanied by structural alterations of the ventricles of heart. 
Reports from the Framingham study suggested a 6-fold increased risk in overall 
mortality in individuals with definite ECG-LVH and 45% deaths due to cardiovascular 
events in these patients (Alan et al., 2006). Moreover, left ventricular hypertrophy 
(LVH) has been identified as an independent risk factor for coronary artery disease, 
sudden death, stroke and also heart failure (Elieser, 1994; Alan et al., 2006). 
  
In the US, it has been estimated that there are 550,000 new cases of CHF every 
year and approximately 4,800,000 Americans are currently diagnosed to have 
congestive heart failure. After the age of 65 incidence of CHF has approached ten per 
1,000 population (1%) in the US (Wayne et al., 2007). CHF patients are believed to 
have a 5 year mortality of approximately 50% (National Heart, Lung & Blood Institute 
CHF fact sheet, 1996) with roughly 20% dying in the first year (Wayne et al., 2007).  
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Myocardial infarction disables 22% males and 46% females within 6 years of 
diagnosis of CHF. 80% of men, while 70% of women under the age of 65 with CHF die 
within 8 years. After CHF is diagnosed, survival is poorer in men than in women, but 
fewer than 15% of women survive more than 8-12 years. Their one-year mortality rate 
is higher with one in five dying. In USA, CHF deaths have increased by 145% between 
1979 and 1999.  
  
The prevalence of LVH in patients with essential hypertension has been found to 
be 40% on average (Alexander et al., 2003). Therefore, prevention and/or regression of 
LVH are major therapeutic goals whether achieved by pharmacologic, mechanical, 
surgical or genetic means. 
  
Here we will discuss the progression of LVH that leads to heart failure with an 
emphasis on the involvement of sympathetic nervous and the renin angiotensin systems. 
 
1.1  Anatomy of the neurons & the neural bed 
The system of cells, tissues and organs that regulate the body’s response to 
internal and external stimuli, through electrical and/or chemical transmission, is known 
as the nervous system (William et al., 2001). It constitutes of brain, spinal cord, nerves, 
ganglia and receptors which harmonize the transmission, reception and response to 
these signals in order to capacitate the body to function.  
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Neurons are the building blocks of the nervous system and constitute of a cell 
body, the dendrites and axon. The cell body contains the nucleus and performs most of 
the functions as a somatic cell except that after maturation most of the neuronal cells 
loose the ability to undergo cell division. Dendrites are small thread like structures 
originating from the cell body and function to receive inputs from the surroundings. 
They may also form junctions with the surrounding neurons to form synapse(s). A pre-
synaptic neuron may release a chemical transmitter called neurotransmitter to 
communicate with the dendrite of a post-synaptic neuron cell body. Axon or a nerve 
fiber is usually elongated and unlike dendrite, it functions to transmit electrical signals 
in the form of action potential, from the cell body to either another synapse or to an 
effector organ. Axons may also branch and thus form collaterals. The beginning end of 
an axon is known as hillock and the terminal end of the axon is called terminal. Axon 
hillock, in most of the neurons, is specialized in initiating the action potential while 
terminal is specialized to release a neurotransmitter (William et al., 2001). 
 
In general the nervous system can be divided into two main subcategories; 
central nervous system (CNS) and the peripheral nervous system (PNS).  
 
1.1.1 Central Nervous System 
The central nervous system (CNS) consists of brain and spinal cord. These two 
organs probably consist of the most delicate tissues in our body. Pertaining to their 
importance they are well protected in our body by three different substances; bone, 
connective tissue and fluid. The outer most layer that protects this delicate tissue is 
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cranium (skull). It surrounds the brain and also constitutes the bony vertebral column 
which surrounds the spinal cord. Between the bone and the nervous tissue are three 
layers of membranes called meninges (dura mater, arachnoids mater and pia mater). In 
between the archnoid mater and the pia mater, the space called subarachnoid space, is 
filled with a fluid called cerebrospinal fluid. The cerebrospinal fluid is a clear watery 
fluid that bathes the CNS and provides a cushion against sudden jerks. It is similar but 
not identical to the plasma in constitution (William et al., 2001). The structure of a 
typical neuron is shown in Fig. 1.1. 
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Figure 1.1. Structure of a typical neuron 
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1.1.2 Peripheral Nervous System 
Peripheral nervous system (PNS) consists of nerve cells that enable 
communication between the CNS and the effector organs throughout the body. The 
peripheral nervous system can be subdivided into two divisions; Afferent PNS and 
Efferent PNS.  
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Figure 1.2 Organization of the nervous system  
[Adapted from William et al., 2001] 
 
 
Afferent division of the PNS consists of neurons that transmit electrical signals 
from organs to the CNS. Information from the visceral organs is transmitted to the CNS 
via these neurons. This information is in regard to blood pressure, hunger, thirst etc 
while the sensory neurons transmit the information related to the external stimuli such 
as vision, touch, taste etc. 
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1.1.2.a Autonomic nervous system 
Autonomic nervous system (ANS) regulates organs of the body that are not 
under voluntary control. It regulates the function of internal organs, glands, vessels, 
cardiac rhythm, kidney function etc. The ANS receives input from parts of the CNS that 
process stimuli from the body and the external environment. These parts of CNS 
include the hypothalamus, nucleus of the solitary tract, reticular formation, amygdala, 
hippocampus, and olfactory cortex. 
 
ANS can be divided into two groups; sympathetic nervous system and 
parasympathetic nervous system. Both sympathetic and parasympathetic systems 
consist of two sets of nerve bodies. The pre-ganglionic body is in CNS while the post-
ganglionic body is usually outside the CNS and these post-ganglionic efferent fibers 
lead to effector organs. 
  
The pre-ganglionic fibers of the sympathetic nervous system are located in the 
inter-mediolateral horn of the spinal cord. The ganglia are usually within the vertebral 
column and long post-ganglionic fibers innervate the effector organs, usually vascular 
smooth muscles, viscera, lungs, scalp, lachrymal and salivary glands, smooth muscles 
of viscera and glands, and ocular muscles. The sympathetic nervous system is catabolic 
in nature and exhibits flight and fright responses. Thus, sympathetic output increases 
heart rate and contractility, bronchodilation, hepatic glycogenolysis and glucose release 
and muscular strength. Less immediately life-preserving functions (e.g. digestion, renal 
filtration) are decreased. Most post-ganglionic sympathetic fibers release noradrenaline 
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and therefore sometimes termed as noradrenergic fibers; i.e., they act by releasing 
noradrenaline (NA).  
 
The pre-ganglionic fibers of the parasympathetic system are located in the brain 
stem and sacral portion of the spinal cord. Pre-ganglionic fibers exit the brain stem in 
the form of cranial (vagus) nerves. The vagus nerve contains most of the 
parasympathetic fibers. Parasympathetic ganglia are found within the effector organ and 
post-ganglionic fibers are usually very small in length. The parasympathetic nervous 
system is anabolic; it conserves and restores, therefore, exhibits rest and digest 
responses. GI secretions and motility (including evacuation) are stimulated, heart rate is 
slowed, and BP decreases.  
 
Erection is a parasympathetic function while ejaculation is a sympathetic 
function. 
 
1.1.2.b Somatic nervous system 
 Somatic nervous system consists of nerve cells called motor neurons which 
control the function of skeletal muscles. These nerves constitute the voluntary control of 
organs. 
 
Here we will focus more on the contribution of sympathetic nervous system and 
renin angiotensin system to LVH progression and thus will discuss them in detail. 
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1.2  Sympathetic nervous system 
The autonomic nervous system (ANS) plays an important role in both healthy 
and diseased states. It regulates the function of all tissues and organs innervated by 
sympathetic nerves, except the skeletal muscles. ANS is independent in its activities and 
is not under voluntary control. It consists of three components; noradrenergic nerves, 
cholinergic nerves and the enteric system. Adrenergic nervous system (sympathetic 
nervous system) is physiologically the most important component of ANS and 
innervates all the vital organs of the body. The cholinergic nerves constitute the 
parasympathetic nervous system. The enteric system regulates the intestinal functions 
and projects from sympathetic and parasympathetic nerves (Furness et al., 1980, Vizi et 
al., 1991) 
  
Here we will emphasize more on the sympathetic nervous system and the role of 
its components in the modulation of haemodynamics.  
  
Sympathetic nervous system consists of a complex relay system consisting of 
nerves, neurotransmitters and receptors. Following are the components that are vital to 
the sympathetic nervous system:  
• Pre-ganglionic sympathetic nerves 
• Post-ganglionic sympathetic nerves 
• Catecholamines 
• Adrenal Medulla 
• Adrenergic receptors 
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 Sympathetic nerves originate in the brain stem and give rise to pre-ganglionic 
efferent nerve fibers that leave the CNS in the thoraco-lumbar region of spinal cord. 
Most of these pre-ganglionic sympathetic nerves form synapses with post-ganglionic 
sympathetic nerves in the para-vetebral chains located on either side of the spinal 
column. Remaining sympathetic ganglia are located in the pre-vertebral ganglia which 
lie in front of the vertebrae. Post-ganglionic sympathetic nerves transmit the signals to 
the innervated tissues by the release of NA and thereby activating the adrenergic 
receptors in the effector tissue/organ and thus producing its actions (Ilia et al., 2000). 
  
The major paracrine factor released by adrenal medulla is adrenaline and to a 
lesser extent noradrenaline (NA). The chromaffin cells of the adrenal medulla are 
innervated by pre-ganglionic sympathetic nerve terminals which uses acetylcholine as 
the neurotransmitter (Ilia et al., 2000). Upon activation of the chromaffin cells, 
adrenaline and noradrenaline are produced. Therefore, we can say that adrenaline and 
noradrenaline are the principle end products of the sympathetic nervous system. 
  
Adrenaline and noradrenaline are catecholamines. They are synthesized from 
tyrosine which is transported into the noradrenergic varicosities by a sodium dependent 
carrier, where tyrosine is converted to di hydroxy phenylalanine (DOPA) by an enzyme 
tyrosine hydroxylase and is finally hydroxylysed to dopamine and a carrier which can 
transport dopamine into the vesicles. Dopamine is converted to NA in the vesicles by 
dopamine bihydroxylase (DBH). In the adrenal medulla, NA is further converted to 
adrenaline. 
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The nerve impulse carried by the sympathetic nerves exerts its actions on the 
effectors through activation of certain receptors in the effector organs. The post-
ganglionic sympathetic nerve terminals release NA to activate these receptors (DiBona, 
2000). Pertaining to the fact that primarily NA and adrenaline activate these receptors, 
they are referred to as adrenergic receptors.  
 
1.2.1 Adrenergic receptors 
 All adrenergic receptors are G-protein coupled receptors. Each major type has 
an affinity for a specific G protein. α1 adrenoceptors show preference for Gq, α2 
adrenoceptors link with Gi while β2 adrenoceptors couple with Gs (Shelli et al., 2004). 
These receptors exhibit a relatively rapid response to agonists. Upon exposure to 
agonists, responses depend on the desensitized state of the receptor (Shelli et al., 2004). 
There are multiple mechanisms involved in the desensitization process. A relatively 
rapid route to desensitization is through phosphorylation of the receptor by both G 
protein receptor kinase and by signaling kinases such as protein kinase A or protein 
kinase C (Luttrell et al., 2002). A slower process to desensitized state of the 
adrenoceptors might exhibit in the form of receptor endocytosis / internalization and 
degradation, which ultimately leads to down regulation of the receptors (Taso et al., 
2001).  
  
Adrenergic receptors are membrane bound receptors in nature and are present in 
cells of both peripheral tissues and CNS. Adrenoceptors mediate a variety of actions 
and therefore have been in the limelight of research for several decades. Ahlquist first 
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classified them as alpha and beta adrenoreceptors in 1948 (Ahlquist., 1948). 
Adrenoceptors excite on exposure to both adrenaline and noradrenaline. Both 
adrenaline and noradrenaline play an important role in the control of blood pressure 
(BP), myocardial contractile rate and force as well as metabolism. Adrenoceptors have 
affinity for many synthetic drugs and with the newer pharmacological tools, scientists 
have been able to identify and subdivide the adrenoceptors. Drugs interacting with 
subtypes have proven useful in a variety of diseases, involving most of the vital organs 
in the body. Some of the pathophysiological conditions in which adrenoceptors have 
been targeted and found to be of use include hypertension, angina pectoris, CHF, 
cardiac arrhythmia and asthma (David et al., 1994).  
 
1.2.1.1 Classification, characterization & distribution 
In early 20th century, Dale reported that certain responses to adrenoceptor 
stimulation, such as the vasopressor action of adrenaline, are insensitive to ergot 
alkaloids that are classical adrenoceptor antagonists. This opened up an exciting new 
avenue for researchers to explore adrenoceptors. Up till then, the focus of adrenoceptor 
classification was based either on “excitatory” or “inhibitory” actions. These qualitative 
approaches of classification were not so helpful and even lead to proposal of different 
neurotransmitters. However, in 1948 Ahlquist’s quantitative approach was based on 
different order of potency of the two different adrenoceptor subtypes. He evaluated 
effects of structurally related natural and synthetic agonists in different tissues. He 
proposed alpha and beta adrenoceptors based on the findings that beta receptors are 
insensitive to blockade by ergot alkaloids (Powell et al., 1957; Moran et al, 1958). In 
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1967, Lands and his colleagues described that there were two subtypes of β receptors. 
They explained that β1 adrenoceptor subtype was equally sensitive to adrenaline and 
NA and that it is the dominant subtype in heart and adipose tissue. Whereas β2 
adrenoceptors were much less sensitive to noradrenaline as compared to adrenaline and 
that they are responsible for relaxation of vascular, uterine and airway smooth muscles 
(Lands et al., 1967 a&b).  
 
 In 1974, Langer presented the classification of α adrenoceptors based on the 
anatomical distribution. Reports started to come in regarding the pharmacological 
differences amongst pre and post junctional α adrenoceptors (Starke et al., 1974). 
Langer suggested that pre junctional α adrenoceptors be named as α2 while post-
junctional as α1. Not much time had passed when a functional subdivision of α 
adrenoceptors was viewed in literature in late 1970’s. These studies used agonists-
antagonists interaction as the basis to oppose anatomical subdivision discussed by 
Langer and other researchers and suggested a classification of adrenoceptors based on 
their function (Berthelsen et al., 1977). These researchers suggested that α1 
adrenoceptors mainly induce excitation while α2 adrenoceptors play a role in inhibition. 
A few years later, Drew and Whiting argued the presence of two distinct types of post 
synaptic α adrenoceptors based on their findings that NA induced vasoconstriction is 
inhibited not only by α1 adrenoceptor antagonists such as prazosin but also with 
yohimbine, a selective α2 antagonist (Drew et al., 1979). These findings lead scientists 
to re-evaluate the way to classify adrenoceptors. In late 1980’s and early 1990’s the 
pharmacological subdivision of α1 and α2 adrenoceptors and their subtypes stirred 
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interest in most scientists. This new classification was based on highly specific agonist 
and antagonist interactions (Ruffolo et al., 1988; Ruffolo et al., 1991). Over the passage 
of time, pharmacological basis of sub classifying adrenoceptors strengthened. Scientists 
agreed that α adrenoceptors that are activated by methoxamine, cirazoline or 
phenylephrine and blocked competitively by low concentration of prazosin, WB-1401 
or corynanthin should be classified as α1 adrenoceptors. Whereas, adrenoceptors 
activated by α-methylnorepinephrine, UK-14, 304, B-HT 920 and/or B-HT 933 and 
blocked by low concentrations of yohimbine, rauwolscine and/or idazoxin be classified 
as α2 adrenoceptors (Ruffolo et al., 1991). 
  
In late 1980’s the advancement in the radio-ligand binding assays, gene 
recombinant technology and development of molecular biology techniques had a major 
impact on adrenoceptor classification. Since then, the presence of several subtypes of α 
and β adrenoceptors have been shown to exist. Sometimes multiple subtypes are 
expressed in a single tissue.  
  
Adrenoceptors have been historically classified into α and β adrenoceptors, 
however, in 1994, David and his co-workers suggested that it is more appropriate to 
classify adrenoceptors into α1, α2 and β adrenoceptors based on differences in affinity to 
pharmacological tools, differences in the second messenger responses and the amino 
acid sequence of these receptors (David et al., 1994). However, in the later studies it 
was shown that there is more than one subtype of β adrenoceptors. These subclasses of 
adrenoceptors are discussed in detail below.   
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1.1.1.2 α adrenoceptors 
 Information regarding modulation of vascular tone through α adrenoceptors 
gained interest by researchers as well as clinicians pertaining to their possible 
manipulation in hypertension. However, what we know about these adrenoceptors today 
is based on their discovery in 1948 by Ahlquist and pioneering work by Langer and his 
co-workers. With the development of selectively binding drugs, these receptors have 
enabled insight into pathological states and their possible treatment. They can be largely 
subdivided into α1 and α2 adrenoceptors. 
 
1.2.1.2.a α1 adrenoceptors 
 α1 adrenoceptors are involved in smooth muscle growth, regulation of blood 
pressure, maintenance of the vascular tone and myocardial contractility (Brodde et al., 
2001; Guimaraes et al., 2001; Koshimizu et al., 2002). A cascade of reactions occurs 
upon stimulation of these receptors, stimulating the activity of Phospholipase C, which 
promotes the hydrolysis of phosphatidylinositol bisphosphate producing inositol 
trisphosphate and diacylglycerol. These molecules act as second messengers mediating 
intracellular Ca2+ release from non-mitochondrial pools and activate protein kinase C 
(Guimaraes et al., 2001). These membrane-bound receptors excite upon coupling with 
both sympathetic neurotransmitters; adrenaline and noradrenaline. Also, each of the α1 
adrenoceptor subtype shows linkage to Gq protein and activates phospholipase C (Shelli 
et al., 2004). 
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With the development in receptor cloning techniques, advancements in 
molecular biology approach and radio-ligand binding assays, α1 adrenoceptors were 
first divided into α1A and α1B subtypes based on relative affinity of these receptors for 5-
MeU, WB-4101 and CEC (Morrow et al., 1986; Han et al., 1987; Gross et al., 1988; 
Hanft et al., 1989 and Boer et al., 1989). These researchers showed that α1A 
adrenoceptors were sensitive to 5-MeU and WB-4101 and insensitive to CEC. They 
also reasoned that α1B adrenoceptors were sensitive to CEC and had a very low affinity 
to 5-MeU and WB-4101. At present researchers discuss at least three sub types of α1 
adrenergic receptors based on a pharmacological classification, namely; α1A, α1B and 
α1D. 
 
1.2.1.2.a.i α1A
 In vitro studies have shown that α1A mRNA is highly expressed in peripheral 
arteries and that up to 90% of total α1 adrenoceptor mRNA is of α1A subtype in 
peripheral vasculature (Guimaraes et al., 2001). Discrepancies exist between the 
knowledge of the expression of these receptors in vitro and their functional implications 
in vivo (Hrometz et al., 1999; Ohmi et al., 1999). It has also been suggested that α1A 
adrenoceptor predominates in 8 different types of rat arteries which had a dense 
innervation of sympathetic nerves (Frank et al., 1998). By inducing chemical 
sympathectomy they also argued that reshuffling of α1A adrenoceptor density might be 
of importance in pathophysiological states with high sympathetic activity. Using 
molecular biology techniques, the presence of another α1 adrenoceptor subtype, termed 
as α1C has been shown to exist (Schwin et al., 1990). In the following years a consensus 
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was reached that α1A/C are the same sub type of alpha adrenoceptor and α1A is to be 
referred to this receptor (Ruffolo et al., 1991). Using binding competition experiments, 
co-expression of α1A and α1B adrenoceptors in rat tail arteries has been shown in intact 
tissue segments and membranes (Tanaka et al., 2004). Recent studies have more clearly 
addressed the functional attributes of these receptors and it has been demonstrated that 
noradrenaline induced contractions in rat tail artery are mediated by both α1A and α1B 
adrenoceptors (Sven et al., 2004). α1A and α1B adrenoceptors have also been shown to 
play a role in the inotropy of mice heart. Using a gene knock out approach, it was 
shown that both α1A and α1B adrenoceptor subtypes play similar roles in exhibiting 
negative inotropy in mouse myocardium. It was also discussed by the same group of 
researchers that the inotropic effects induced by α1 adrenoceptors differ dramatically in 
mouse and rat myocardium (Diana et al., 2002). In humans, α1A and α1B subtypes of 
adrenoceptors have also been shown to be the major expressed and functionally 
important sub types in the sphenous vein (Ming et al., 2001).  
 
1.2.1.2.a.ii α1B
 α1B was probably the first α1 adrenoceptor subtype to be cloned using molecular 
biology techniques. Cotecchia and his fellow workers isolated a clone from a hamster 
vas deferens cell line (DD1MF2), which expressed a protein with a sequence similar to 
that of a G protein coupled receptor (Cotecchia et al., 1988). Upon further analysis and 
expression of this cDNA resulted in a protein with properties consistent with α1B 
adrenoceptor. It had a high affinity for prazosin and a low affinity for phentolamine, 5 
methyl urapidil (5-MeU) and yohimbine. It was also highly sensitive to irreversible 
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inactivation by CEC. Voigt and fellow colleagues identified rat α1B adrenoceptors in 
liver, spleen, heart and cerebral cortex and showed that its pharmacological profile was 
similar to that of hamster (Voigt et al., 1990). In one of the recent studies, it was shown 
that noradrenaline mediates sympathetic neurotransmission in murine mesenteric 
arteries by acting on α1B adrenoceptors and to a lesser extent on α1A adrenoceptors. The 
same experiment also revealed that in DOCA salt hypertensive mice, neurogenic 
constrictions are mediated only by α1B adrenoceptors (Alex et al., 2005). Using α1B 
knock out mice, a definite but minor role of α1B adrenoceptors in the rat tail arteries has 
also been discussed recently (Daley et al., 2002). 
  
1.2.1.2.a.iii α1D 
 In 1991, Lomasney and his fellow researchers reasoned for the presence of 
another α1 adrenoceptor subtype based on their findings from molecular cloning and 
cDNA expression from the rat cerebral cortex. Their theory was fortified by Perez and 
co-workers who called this as α1D adrenergic receptor (Lomasney et al., 1991). They 
found low affinity for the more selective α1A adrenoceptor antagonist 5-MeU and (+) 
niguldipine (Lomasney et al., 1991). It has been established by gene knock out studies 
in mice that α1D play an important role in homeostasis. In vivo studies showed that α1D 
adrenoceptors play an important role in the vascular contractions caused by α1 
adrenoceptor agonists (Piascik et al., 1995; Hussain et al., 2000). Removal of the genes 
regulating α1D reduced the resting blood pressure in mice but α1B knock out mice did not 
show any baseline change in the pressure, suggesting an important role of α1D 
adrenoceptor subtype in maintaining homeostasis. These scientists also suggested that 
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α1D is an important adrenoceptor subtype in the development of secondary hypertension 
in acute renal dysfunction (Chihiro et al., 2005). One of the studies has shown that α1D 
adrenoceptors do not play a role in neurogenic constrictions in both the arteries of sham 
and DOCA hypertensive mice (Alex et al., 2005). Moreover, a recent study suggests 
that in hyper homocysteinemia, the contractile responses to phenylephrine are due to 
impaired modulation performed by α1D adrenoceptor mediated endothelial 
vasorelaxation in rat carotid arteries (Claudia et al., 2006).  
  
At present a consensus has been reached as to the presence of three α1 
adrenoceptors namely; α1A, α1B and α1D. Identifying the subtype of α1 adrenoceptors 
involved in vasoconstrictive responses to sympathomimetic agonists is by no way 
straightforward. In vitro studies suggested that vascular smooth muscles express mixed 
subtypes of α1 adrenoceptor subtypes (Miller et al., 1996). Evidence also suggests that 
responses produced are probably due to the activation of more than one subtype (Zhong 
et al., 1999).  Although mRNA of all three subtypes have been found in several blood 
vessels, the contraction in response to phenylephrine is primarily mediated by α1D and 
secondarily by α1B adrenoceptors (Xu et al., 1997; Hussain et al., 2000). In another 
study Piascik and co-workers made similar observation. They found that expression of 
mRNA for α1 adrenoceptor subtypes, in several arteries of rat, were in order 
α1A>α1B>α1D but only α1B played a functionally important role in mesenteric artery 
(Piascik et al., 1997) whereas α1D adrenoceptor subtype dominated the functional 
importance in aorta, femoral and iliac arteries (Piascik et al., 1997). Some functional 
studies show that in the rat, α1A and α1D adrenoceptor subtypes regulate the larger 
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vessels, while α1B dominate the functional importance in the small resistance vessels 
(Piascik et al., 1997; Gisbert et al., 2000). Some studies have also discussed the 
possibility of junctional versus extra junctional localization of α1 adrenoceptor subtypes. 
However, their physiological significance and differential localization based on the 
functional studies remain to be clinically exploited (Alex et al., 2005).  
 
1.2.1.2.a.iv α1L & α1H
 Another classification of α1 adrenoceptors based on the relative affinity for 
prazosin exists. α1H showed high affinity to prazosin while α1L showed low affinity 
(Holck et al., 1983; Langer et al., 1984; Flavahan et al., 1986). This point of view 
emerged because some scientists observed that two types of α1 adrenoceptors did not 
show any response to noradrenaline induced contractile responses of propranolol in 
prostate and bladder of rat and guinea pig (Cohen et al., 1989). More recently, scientists 
have shown that α1L adrenoceptors mediate the noradrenaline induced contraction in 
mouse prostate (Katherine et al., 2006). These results are in accordance with the 
findings of Ford and co-workers, that the same receptor induces contractile responses in 
human prostate (Ford et al., 1996). 
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1.2.1.2.b α2 adrenoceptors 
 α2 adrenoceptors were first discussed in 1980’s. Pertaining to the non-
availability of selective agonists, as in the case of α1 adrenoceptors, α2 adrenoceptors 
and their subtypes classification was by no means easy. Binding studies initially 
revealed two subtypes of α2 adrenoceptors namely α2A from human platelets and α2B 
from rat kidney, lungs and cerebral cortex (Van Zwieten et al., 1982; McGrath et al., 
1989). To date, three subtypes of α2 adrenoceptors have been shown to exist, namely; 
α2A/D, α2B and α2C (Guimaraes et al., 2001). These findings were initially based on 
radioligand binding assays but later functional studies and molecular approaches 
confirmed their expression as well. The amino acid composition of α2B and α2C are 
similar in mammalian species except for α2A adrenoceptor, which differs slightly. In 
humans the gene coding for α2A, α2B and α2C adrenoceptors are located in chromosomes 
10, 2 and 4 respectively (Regan et al., 1988; Lomasney et al., 1990; Weinshank et al., 
1990). Pharmacologically α adrenoceptor antagonists possess different affinity for α2 
adrenoceptor subtypes (Guimaraes et al., 2001). Prazosin has a relatively higher affinity 
for α2B and α2C adrenoceptors and a very low affinity for α2A/D adrenoceptors. 
Yohimbine and rauwolscine are more selective than phentolamine and idazoxanon for 
α2A in comparison to α2D adrenoceptors.  
   
A vast majority of tissues express more than one subtype of α2 adrenoceptors 
with a few exceptions; α2A in human platelets, α2B in the rat neonatal lung and α2C in 
opossum cells (Bylund et al., 1988). It has been discussed that α2 adrenoceptors are an 
essential part of the neural system regulating cardiovascular function (Ruffalo et al., 
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1991). However, at the post junctional level, α2 adrenoceptors were not found in vitro in 
most of the arterial vessels. Also, in general, the vasoconstrictive effect of α2 
adrenoceptors is restricted in general to the small arteries and arterioles but not in large 
arteries (Guimaraes et al., 2001).   
   
The involvement of α2 adrenoceptors and/or imidazoline receptors in the anti-
hypertensive effects of drugs like clonidine and moxonidine is still controversial. The 
results of one study suggests that the effects of moxonidine acting in the forebrain (renal 
vasodilatation) depends on α1 adrenoceptor activation, while the cardiovascular effects, 
including renal vasodilatation, produced by moxonidine acting in the brainstem depends 
at least partially on the activation of α2 adrenoceptors (Thiego et al., 2007). 
 
1.2.3  β adrenoceptors 
 These are G protein coupled receptors and mediate cardiovascular responses to 
noradrenaline released from sympathetic nerve terminals and to circulating adrenaline. 
Also, β adrenoceptor mediated vasodilatation plays an important physiological role in 
the regulation of vascular tone. Stimulation of peripheral β adrenoceptors lead to 
relaxation of the vascular smooth muscles, thereby controlling the peripheral vascular 
resistance. β adrenoceptors can be stimulated or blocked by many compounds. Such 
compounds are therefore used to treat important and common diseases, such as 
hypertension, asthma, cardiac arrhythmias and ischemic heart disease (Guimaraes et al., 
2001).  
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All β adrenoceptor subtypes signal by coupling to the stimulatory G-protein; Ga. 
This leads to the activation of adenylyl cyclase and release of the second messenger 
cAMP (Dixon et al., 1986; Frielle et al., 1987; Emorine et al., 1989). However, some 
recent studies indicate that, under certain circumstances, β adrenoceptors, particularly 
β3 adrenoceptor, can couple to Gi as well as to Gs (Chaudry et al., 1994; Xiao et al., 
1995; Gauthier et al., 1996, Gauthier et al., 2000). Intracellular events following β-
adrenoceptor activation are also linked to ion transport. It is well known that protein 
kinase A activated by cAMP, phosphorylates L-type Ca2+ channels to facilitate Ca2+ 
entry and thus producing the positive inotropic effect in atria and ventricles, increased 
heart rate in the sino-auricular node, and accelerated conduction in the atrio-ventricular 
node (Guimaraes et al., 2001). Multiple mechanisms control the signaling and density 
of G-protein-coupled receptors (GPCRs). The termination of GPCR signals involves 
binding of proteins to the receptor as a first step. This process is initiated by serine-
threonine phosphorylation of the receptors. This phosphorylation takes place both by 
members of the GPCR kinase family and by second-messenger-activated protein 
kinases A and C. Receptor phosphorylation by GPCR kinase is followed by binding of 
proteins named arrestins. Arrestins bind to the phosphorylated receptor and inhibit 
further G-protein activation (Luttrell et al., 1999). 
  
In late 1960s Lands and coworkers classified β receptors into β1 and β2 (Lands 
et al., 1967 a&b). So far three distinct β adrenoceptor subtypes have been cloned; β1, 
β2, and β3. β1 adrenoceptors mediate +ve chronotropy and ionotropy as well as 
relaxation of the coronary arteries and stimulates the renin release (Bylund et al., 1994). 
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The indigenous catecholamines adrenaline and noradrenalin have an excitatory action 
on both β1 and β2 adrenoceptors whereas propranolol antagonizes them. Three different 
genes located on human chromosomes 10, 5 and 8 encode β1, β2, and β3 respectively. 
The human β3 adrenoceptor has 49% and 51% overall homology at the amino acid level 
with β2 and β1 adrenoceptors, respectively (Emorine et al., 1989; Granneman et al., 
1994).  β3 adrenoceptors are not blocked by propranolol and other conventional β 
adrenoceptor antagonists. However, this subtype of β adrenoceptors can be selectively 
blocked by SR-59230. Moreover, they are activated by selective β3 adrenoceptor 
agonists like BRL 37344 and CL 316243 (Manara et al., 1995; Summers et al., 1997; 
Fischer et al., 1998). 
 
On the basis of many pharmacological and molecular studies, the existence of a 
fourth β adrenoceptor subtype was postulated (Brodde et al., 1999). Studies using more 
selective agonists and antagonists showed that relaxation of vascular smooth muscle 
cells resulted from activation of either β1 or β2 adrenoceptor subtypes and that the 
involvement of each subtype depended on the vascular bed and the species under 
investigation (O’Donnell et al., 1984; Guimaraes et al., 1993; Shen et al., 1994; Shen et 
al 1996; Begonha et al., 1995).  
  
In the heart, maximum +ve ionotropy is obtained by stimulation of only β1 
adrenoceptors (Kaumann et al., 1989; Motomura et al., 1990) while the –ve ionotropy 
induced by β2 adrenoceptors is larger than that induced by the β1 adrenoceptor 
stimulation in the vessels (Guimaraes et al., 1981).  
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